Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALKBH3 | Q96Q83 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054750 | 0.85 | KDM4E (0.56) | AURKAKDM4ETDP1L3MBTL1LMNA | |
| SCHEMBL3502168 | 0.83 | KDM4E (0.47) | AURKAKDM4ETDP1L3MBTL1LMNA | |
| SCHEMBL3502120 | 0.81 | AURKA (0.53) | AURKAKDM4ETDP1L3MBTL1LMNA | |
| SCHEMBL3501351 | 0.81 | KDM4E (0.59) | AURKAKDM4ETDP1L3MBTL1LMNA | |
| SCHEMBL3503054 | 0.79 | KDM4E (0.52) | AURKAKDM4ETDP1L3MBTL1LMNA | |
| SCHEMBL1054292 | 0.79 | AURKA (0.64) | AURKAKDM4ETDP1L3MBTL1MAPT | |
| SCHEMBL1052301 | 0.79 | AURKA (0.69) | AURKAKDM4ETDP1L3MBTL1MAPT | |
| SCHEMBL1054586 | 0.79 | AURKA (0.53) | AURKAKDM4ETDP1L3MBTL1MAPT | |
| SCHEMBL3500883 | 0.78 | AURKA (0.64) | AURKAKDM4ETDP1L3MBTL1LMNA | |
| SCHEMBL4305932 | 0.78 | AURKA (0.52) | AURKAKDM4ETDP1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-6800760-B2 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6774237-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES INHIBITORS; ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS | CHIRON CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-6762194-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | CHIRON CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | AURKA 1124/4885KDM4E 4563/4885TDP1 1883/4885 |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | VEGFA, FLT1, KDR | AURKA 265/4885KDM4E 3745/4885TDP1 1197/4885 |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | KDR, FLT4, FLT1 | AURKA 30/4885KDM4E 776/4885TDP1 3258/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | AURKA 1124/4885KDM4E 4563/4885TDP1 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.